depression and anxiety in practice Flashcards
classification system for depression
DSM-5
diagnosis of depression using DSM-5
diagnosed if > 5 symptoms
low intensity psychosocial interventions
- individual guided self help (based on CBT)
- computerised CBT
- structured group physical activity programme
pharmacological interventions
antidepressants
high intensity psychosocial interventions
CBT
interpersonal therapy (IPT)
What should choice of antidepressant depend on?
accceptability s/e profile patient preference previous experience of treatments discontinuation symptoms safety in OD (inc risk with TCAs) interaction potential (drug/disease)
recommended SSRIs to prescribe
generic
CVD and QT prolongation
- all antidepressants can cause QT prolongation
- med Hx, lab monitoring and baseline ECG to ID pts at risk of QT prolongation before starting antidepressant
- drug drug interactions can cause QT prolongation
risk factors for QT prolongation
- cardiac conditions (bradycardia, MI, HF)
- electrolyte disturbances (hypokalaemia, hypomagnesemia, hypocalcaemia)
- female
- genetic polymorphisms
- > 65yrs
- congenital long QT syndrome, inherited cardiac abnormalities
- meds/disease that prolongs QT interval/affects electrolytes (diuretics, renal dysfunction)
- Hx of QT prolongation
citalopram/escitalopram
associated with dose dependent QT interval prolongation
avoid in:
- congenital long QT syndrome
- known pre-existing QT interval prolongation
- comb with meds that prolong QT interval
ways to prevent QT prolongation
- ECG mesaurements for patients with cardiac disease
- electrolyte disturbances should be corrected before starting Tx
antibiotics that can prolong QT
erythromycin
clarithromycin
citalopram max daily doses
40mg adults
20mg >65yrs
20mg hepatic impairment (metabolism slowed, higher serum levels, inc QT prolongation risk)
escitalopram max daily dose for >65yrs
10mg/day
When are further dose reductions done for citalopram/escitalopram?
first 2 weeks of treatment in patients with mild/moderate hepatic impairment
poor metabolisers of CYP2C19
CYP2C19 inhibitors and antidepressants
they inhibit metabolism of antidepressant and increase their serum levels
gastroprotection and SSRIs
gastroprotection (PPIS) recommended for pts at risk of bleeding disorder taking SSRIs
omeprazole is CYP2C19 inhibitor, caution, could inhibit its metabolism and cause QT prolongation
antidepressants and # risk
small inc risk with TCAs and SSRIs
antidepressants and postpartum haemorrhage
small inc risk of postpartum haemorrhage when SSRI/SNRI used in month before delivery
general adverse effects of antidepressants
- inc in agitation, anxiety starting Tx
- suicidal thoughts and suicide attempts early in Tx or after stopping esp adolecents/young adults <30yrs, Hx suicidal behaviour, monitor behaviour
- hyponatraemia
- sexual dysfunction
- withdrawal effects
hyponatraemia
- most antidepressants, SSRIs high risk
- more common in elderly
- dizziness, drowsiness, confusion, nausea, muscle cramps, seizures
- usually within 30 days of starting, can take months
- transient or persistent
- stop antidepressant and Na levels normal within 1-2 weeks
- urgent care if severe, Na <125mmol/L
- withdrawal symptoms may occur
- once Na normal, different antidepressant (diff class)
How do SSRI/SNRI inc bleeding risk?
by reducing the uptake of serotonin by platelets
reduce the ability of platelets to aggregate and inc risk of haemorrhage, esp GI bleeding
factors that inc risk of bleeding with SSRIs/SNRIs
- elderly
- patients with Hx of peptic ulcers
- excessive alcohol use
- co-administration with other drugs that have bleeding risk (NSAIDs, antiplatelets, CS, warfarin)
How to reduce bleeding risk with SSRIs/SNRIs?
- avoid SSRI/SNRI if at inc risk
- avoid concomitant drugs that inc risk
- if no alt, gastroprotection
- gastroprotection in older people taking NSAIDs/aspirin